Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Ron, Here is a co.

Ron, Here is a co.

posted on Dec 06, 2005 01:28PM
that you may want to contact while doing your research on Swartz. I don`t know the details, but thought it was very sad in light of the ``Christian`` work that he is supposed to be doing. I left the telephone and email #s in the safe harbor section and this info came from 2 different sources. Thanks for what you are doing, ads

of September 30, 2002, our current liabilities exceeded our current assets by $5,473,263, and our auditors included a “going concern” footnote in our audited financial statements for our last fiscal year ended December 31, 2001; · We are currently in arrears in the payment of approximately $230,000 of payroll taxes; · The outcome of our pending litigation with The Zondervan Corporation; · The outcome of threatened litigation with Swartz Private Equity, LLC; · The sufficiency of our existing capital resources and our ability to raise additional capital to fund cash requirements for future operations; · Our ability to meet ongoing royalty payment obligations; · Our ability to sustain sales of major product lines notwithstanding the removal of certain highly acknowledged and popular content; · Our dependence on third parties to fulfill a significant portion of our orders; · Uncertainties involved in our ability to introduce new products; · Our ability to retain key executives and other personnel; · Product returns exceeding reserves; · Potential infringement on our part of the intellectual property rights of others; and · General economic conditions.

In 2000, the Company entered into and subsequently terminated an investment Agreement with Swartz Private Equity LLC (``Swartz``). The investment agreement entitled the Company, at the Company`s option, to issue and sell its common stock for up to an aggregate of $15 million from time-to-time during a three-year period through April 2003, subject to certain conditions including

(1) an effective registration statement must be on file with the SEC registering the resale of the common shares, and (2) a limitation on the number of common shares which can be sold to Swartz within a 30 day time period based on the trading volume of the stock, among others. Swartz could purchase the common stock from the Company at a discount ranging from 9% to 25% depending on the price of the common stock. In addition to the common stock purchase, Swartz received warrants to purchase an additional 10% of the common stock equal to 110% of the market price as determined during the pricing period, subject to further semi-annual adjustments if the price of the common stock goes down. The registration statement went effective on July 12, 2000. During 2000 pursuant to this agreement, the Company sold 202,430 shares of common stock and issued 779,024 warrants to purchase shares of the Company`s common stock at exercise prices ranging from $0.23 to $0.28 with exercise periods of five years from date of grant. The sale of stock has been recorded net of related offering costs of approximately $35,000. As of September 30, 2001, none of the warrants have been exercised. This equity financing agreement did not provide the necessary resources to pursue the Company`s acquisition strategy; therefore, the agreement was terminated effective October 16, 2000.

Concurrently with the closing of the Barron Partners, LP transaction, FindEx concluded a settlement with Swartz Private Equity, LLC, with which it had been involved in an ongoing dispute for several years. The terms of settlement are deemed favorable by management and the company’s board of directors.

Steven Malone, President of FindEx, stated, “We are pleased to have completed this transaction with Barron Partners. Barron has a track record of doing their homework on companies and only investing in those that they believe have strong upside potential and a solid plan for the future. We believe that their decision to invest in FindEx is a strong endorsement of our business plan and our market potential. The proceeds from this first round of financing has allowed us to resolve our long-standing dispute with Swartz, and will allow the company to clean up its balance sheet and accelerate its development and marketing plan to grow the company.”

FindEx is a developer, publisher, and distributor/seller of off-the-shelf consumer and organizational software products. The common thread among the Company`s products is a customer constituency that shares a devotion to or interest in Christianity and faith-based ``inspirational`` values. We are focused on becoming the premier provider of Bible study and related faith-based software products and content to the domestic and international markets. Our flagship product is QuickVerse®. QuickVerse® simplifies biblical research with powerful searching that anyone can use to find information across multiple Bibles and reference books. QuickVerse® includes customizable options for daily Bible reading, and devotional and in-depth Bible study. One of our PDA Editions, specifically made for the Pocket PC® or Palm OS®, enables users to take their studies with them anytime, anywhere. For product information see: www.quickverse.com.

Safe Harbor

This press release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933,as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature

Contact Information: FindEx.com, Inc. Kirk Rowland (402) 333-1900 Email: investor@quickverse.com Website: www.quickverse.com

Share
New Message
Please login to post a reply